A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 1995

Study Completion Date

December 31, 2000

Conditions
HIV InfectionsImmunologic Deficiency SyndromesLymphoproliferative Disorders
Interventions
DRUG

all-trans-retinoic acid with IFN-alpha2a

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH